DYRK1A as a novel target for glioblastoma therapies [ 2016 - ]

Research Grant

Researchers: A/Pr Lenka Munoz (Principal investigator) ,  Prof Michael Kassiou (Principal investigator) ,  Prof Terrance Johns

Brief description Glioblastoma is a form of brain cancer that is currently incurable. We have discovered that switching-off an enzyme called DYRK1A (using ‘DYRK1A inhibitors’) kills glioblastoma cells. This therapeutic advantage is even greater when combined with drugs approved for other cancers. This project will develop new DYRK1A inhibitors and examine a novel combination treatment for glioblastoma patients. This could initiate a novel therapy that could significantly extend patients’ lives.

Funding Amount $620,294.00

Funding Scheme Project Grants

Notes Standard Project Grant